Reason for request
Inclusion on the list of medicines reimbursed by National Health Insurance and approved for use by hospitals.
Clinical Benefit
| Substantial |
The actual benefit of RANEXA in this indication is substantial. |
Clinical Added Value
| no clinical added value |
RANEXA should be used only by patients with stable angina that is inadequately controlled or who are intolerant to betablockers and/or calcium channel blockers.
Given the data available, RANEXA does not provide any improvement in actual benefit (IABV) in the management of these patients. |
eNq1mFFv2jAQx9/5FFHeSQgtK0yBamNlQ2o1Ros27aUyyVHMgp2ebUj36ecQqtHJUVeDH2M7/7v4/v75lPiyWGfeBlBQzvp+FLR8D1jCU8oe+v7sbtTs+peDRrwiG3Kw7CJoBVHb95KMCNH3y9lgDoSJ4MfN9SfQ7wP6g4YX8/kKEvlinZI0C74QsbwhebnGizecpt4a5JKnfT9XcjfqxUKizmKw5fhL5CSBONyPHM6u7s8Px+OwFPsPVSUArwl7MIoCs9JMFCIwOSQSHjg+1eR7ZqVNxRQEV5jAhMjlBPmGppAaQyxIJsAqyGKb3gJuMpBlEKN4uErWwkqcrEgxhcexOekPenYoC9lsNaOLbnTei1qddvuiYxUKD7bKXAX9EWFy3+2etXutEFiIhEFBLCsz4ShJ5qgmVAxf2spRHITHV2ufUpFn5ClYidx2qwgSPQ2oD7+7Dym/4E6XVGR6z/7RZyrLwjdmPdvDwlHGJYuGXDFZw4zR1HYjhpxJKOoraoc5Wey9SEGcTvY3Z2bET9Q8o4kt0DRyFAg5m47reXY6FHwkAmbojgXfKUv5VpyeMYc1dZR9vsOkUTTHNLpv97rvok7H+gj91AaquV2uFPIcQk0fKo6Bypgt+LE40Z40Sz078kRm3HU4PCEZ1PQ4TUuuaBc+t2TOfO7uDFUTRtHPV3e25vimAJ9ud49GaZr2n8tqx1wXINdOrM377b6ujreT5lehGRtLKXPxPgy3222wJKIpiN6lYIEnhvrBLequ8XZyVVetSwVGR6nPqxvvbfWxPWavXebHNqj79/eNsDGGRAVH1KIisjNujq9Oj+K/3amztCcv2OEuzK6TJJJy5qrHUXOj4lHw12VlI9R8+LpY0Jr/ILW2jMPqH8ygEYfl/5dB4w8C6+Ha
aZ0FC63J4j4kVJhK
